Outcomes of testing for KRAS exon 2 in the medical records review study.

CI, confidence interval; mCRC, metastatic colorectal cancer.aThree patients did not have a KRAS test performed (one in Round 1 and two in Round 2), and one patient had a KRAS test performed after the first dose of panitumumab (Round 1).bTwo patients had a mutant KRAS test result confirmed prior to first dose of panitumumab (one in Round 1 and one in Round 2) and one patient had an unknown KRAS test result (Round 2).cReceived oxaliplatin-containing chemotherapy at any time during the interval from 7 days prior to the date of first dose of panitumumab, until 7 days after the last dose of panitumumab.dOne patient did not have a KRAS test performed (Round 1), and one patient had a KRAS test performed after the first dose of panitumumab (Round 1).Outcomes of testing for KRAS exon 2 in the medical records review study.